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Strengths and limitations of this study
 ► Validation of the Vision Impairment Screening 
Assessment (VISA) screening tool in this prospective 
study shows improved detection accuracy for detec-
tion of stroke- related visual impairment.
 ► The study included clinicians involved in stroke care 
who are not specialists in vision problems and lack 
formal eye training.
 ► Where early visual impairment detection occurs, this 
facilitates prompt referral with fewer false positives 
and negatives.
 ► Through process evaluation, clinicians reported ac-
ceptability of the VISA screening tool for is use in 
screening for presence of vision problems in stroke 
survivors.
 ► The VISA screening tool may further be of potential 
use for visual screening in other care settings such 
as neurorehabilitation.
AbStrACt
Purpose Screening for visual problems in stroke 
survivors is not standardised. Visual problems that remain 
undetected or poorly identified can create unmet needs for 
stroke survivors. We report the validation of a new Vision 
Impairment Screening Assessment (VISA) tool intended for 
use by the stroke team to improve identification of visual 
impairment in stroke survivors.
Methods We conducted a prospective case cohort 
comparative study in four centres to validate the VISA 
tool against a specialist reference vision assessment. 
VISA is available in print or as an app (Medicines and 
Healthcare products Regulatory Agency regulatory 
approved); these were used equally for two groups. Both 
VISA and the comprehensive reference vision assessment 
measured case history, visual acuity, eye alignment, eye 
movements, visual field and visual inattention. The primary 
outcome measure was the presence or absence of visual 
impairment.
results Two hundred and twenty- one stroke survivors 
were screened. Specialist reference vision assessment 
was by experienced orthoptists. Full completion of 
screening and reference vision assessment was achieved 
for 201 stroke survivors. VISA print was completed for 
101 stroke survivors; VISA app was completed for 100. 
Sensitivity and specificity of VISA print was 97.67% and 
66.67%, respectively. Overall agreement was substantial; 
K=0.648. Sensitivity and specificity of VISA app was 
88.31% and 86.96%, respectively. Overall agreement was 
substantial; K=0.690. Lowest agreement was found for 
screening of eye movement and near visual acuity.
Conclusions This validation study indicates acceptability 
of VISA for screening of potential visual impairment in 
stroke survivors. Sensitivity and specificity were high 
indicating the accuracy of this screening tool. VISA is 
available in print or as an app allowing versatile uptake 
across multiple stroke settings.
IntroduCtIon
The prevalence of overall visual impair-
ment has been estimated at 65%–73% with 
varying prevalence reported for specific types 
of visual impairment (inclusive of reduced 
central vision, ocular motility defects, visual 
field loss and visual perception problems).1–4 
Figures for the incidence of new- onset visual 
impairment following stroke are placed at 
about 60%.4 Given the estimated 100 000 
new- onset strokes per annum in the UK there 
are sizeable numbers of stroke survivors living 
with stroke- related visual impairment.5
Visual impairment constitutes a consider-
able comorbidity of stroke. Visual impair-
ment, on its own or in addition to other 
stroke- related disabilities, can cause signif-
icant impact to quality of life.6 For many, it 
results in inability or altered ability to under-
take many aspects of daily activities with impact 
on return to work, participation in hobbies 
and family life, and can lead to social isola-
tion, altered mood and depression.7–9 Inter-
ventions for stroke- related visual impairment 
are well established10 but require referral to 
appropriate eye care services, which is facil-
itated through orthoptic service routes.11 
Where visual impairment is identified, this 
facilitates optimisation of other therapy and 
early access to vision rehabilitation.
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There are issues with how best to identify the pres-
ence of visual impairment through stroke team vision 
screening and specialist vision assessment.12 Even with 
screening measures in place there are also issues reported 
with provision of care and access to vision services for 
stroke survivors who have been identified as having vision 
problems.13
The overall aim of this study was to validate the Vision 
Impairment Screening Assessment (VISA) tool which 
uses simple established assessments of visual function 
coupled with detailed instructions. Our objectives were 
to test VISA, available in print or as a software applica-
tion, against a reference of a specialist vision assessment 
to determine sensitivity, specificity, predictive values 
and inter- rater agreement of results between VISA and 
specialist vision assessments.
MethodS
The development and pilot validation of VISA have been 
described elsewhere.14 This study is reported in accor-
dance with the STandards for Reporting of Diagnostic 
accuracy (STARD) guidelines.15
design
A prospective case cohort comparative design was used 
for the validation clinical study between September 2016 
and February 2019. Individuals were suitable for inclusion 
if they were 18 years of age or older, had clinical diagnosis 
of stroke as defined by WHO, had the ability to agree to 
vision screening using verbal or non- verbal indications 
of agreement, did not have severe cognitive impairment 
preventing screening defined as difficulty with memory/
concentration/decision making and thus being unable to 
follow instructions, and did not decline vision screening. 
This was a convenience sample of participants who were 
identified as being eligible from inpatients on the acute 
stroke unit. With recruitment on the acute stroke unit, 
time to VISA assessment was typically within 1 week of 
stroke onset. Our inclusion criteria were intended to be 
pragmatic and inclusive of as many stroke survivors as 
possible. All participants provided informed consent.
Setting, recruitment and assessment
Recruitment took place across five hospitals (secondary 
hospital care) in which an orthoptist was a member of the 
core acute stroke unit multidisciplinary team (MDT) (as 
per national guidelines: Royal College of Physicians Inter-
collegiate Stroke Guidelines and British & Irish Orthoptic 
Society extended guidelines for stroke practice).16 17
For the purpose of this study, vision screening was 
undertaken with VISA and screening was defined as the 
assessment of stroke survivors for the presence of reduced 
visual function against preset abnormality criteria, 
outlined in the statistical methodology section.
Specialist visual assessment was defined as the vision 
assessment undertaken by an orthoptist in which detec-
tion of visual impairment was coupled with formal 
diagnosis of the type of visual condition present. As a 
minimum this consisted of near and distance LogMAR 
(Logarithm of the Minimum Angle of Resolution) visual 
acuity, cover test, ocular motility assessment, standardised 
visual field to confrontation using 10 mm red targets and 
visual inattention assessment.
Each stroke survivor underwent two vision assessments: 
the routine orthoptic specialist vision assessment and 
the VISA screening assessment. Patients were recruited 
consecutively as being identified to meet the inclusion 
criteria and providing consent to participate.
VISA was available in print and as a software app. VISA 
was used in print form for the first half of recruitment 
and, subsequently in app form for the second half of 
recruitment to this study. Both VISA formats consisted 
of five VISA sections comprising case history, LogMAR 
visual acuity at near and distance, eye alignment and 
movement, visual fields and visual inattention. A sepa-
rate section comprising stand- alone user instructions is 
included. In brief, VISA consists of five sections. Section 1 
comprises a case history with questions and observations 
of visual symptoms and signs. When it is not possible to 
obtain a case history from the patient, the tool advises to 
consult family members/carers. The person completing 
the screen is instructed to observe for abnormalities of 
lids, pupils and head position among other vision signs. 
Section 2 comprises an assessment of LogMAR visual 
acuity for near (35 cm) and distance (3 m); monocular 
or binocular depending on the ability of the patient. A 
matching card was available for patients who were unable 
to name letters but could point to letters. For those unable 
to comply with any letter test, a further option included 
grating cards that use a preferential looking technique 
which is particularly useful with cognitive/communica-
tion issues. Section 3 is an assessment of eye alignment 
observing symmetry of the corneal reflections of each 
eye. Clinician observations can be compared with images 
of straight eyes or images of eyes in converged, diverged, 
elevated or depressed strabismus positions. Eye move-
ments (smooth pursuits) assessed full movements of each 
eye into up, down, right and left gaze positions. Clini-
cian observations could be compared with images of full 
ocular rotations to right/left gaze, elevation/depression 
and on convergence. Section 4 is an assessment of visual 
field, and section 5 is an assessment of visual inattention 
including line bisection, clock drawing and a cancellation 
task. The print and app versions are identical with the 
exception of the visual field assessment. In VISA print, 
a standardised method of confrontation is conducted. 
Confrontation follows a typical method with the clinician 
seated directly opposite the patient at a distance of 1 m 
and following stages that involve the patient indicating 
when a 10 mm red target is seen in the periphery of their 
vision, finger counting in each quadrant of the visual field 
and comparison of examiner facial features. In VISA app, 
a kinetic visual field assessment is undertaken which, at 
a test distance of 30 cm and a screen width of 24.6 cm, 
allows an assessment of the 40° visual field. The patient is 
 o
n
 June 25, 2020 at BVA. Protected by copyright.
http://bmjopen.bmj.com/
BM
J O
pen: first published as 10.1136/bmjopen-2019-033639 on 11 June 2020. Downloaded from 
3Rowe FJ, et al. BMJ Open 2020;10:e033639. doi:10.1136/bmjopen-2019-033639
Open access
asked to fixate a static fixation point in the corner of the 
screen while a stimulus moves from the other edges. They 
are asked to tap the tablet screen when the stimulus is 
seen. This is repeated with the fixation target positioned 
at all four corners of the screen.
Section 5 includes three routine assessments for visual 
inattention; line bisection, clock drawing and a cancel-
lation task. The line bisection task requires the patient 
to indicate the centre of line for three lines of differing 
lengths. The cancellation task requires the patient 
to cross out large clock symbols among distractors of 
small clock symbols and large/small open circles. Clock 
drawing requires the patient to draw the numbers and 
clock hands on a blank circle. VISA app collates data from 
each of the sections to create a PDF record of the assess-
ment. The free- to- access VISA tool is available on; www. 
vision- research. co. uk.
The routine orthoptic vision assessment comprised 
detailed diagnostic assessments of case history, visual 
acuity, ocular alignment and movement, visual field and 
visual perception. This assessment was undertaken within 
24 hours (typically the same day) of the VISA screen—
to minimise effect of potential recovery. The orthoptic 
assessment covered all assessment sections included 
in the VISA tool. However, the orthoptist undertook 
a detailed assessment using their specialist expertise to 
interpret the results and adapt testing methods to indi-
vidual requirements.
The order of the VISA screening and orthoptic vision 
assessments varied in a pragmatic manner to avoid the 
effects of fatigue and bias towards either the screen or 
orthoptic vision assessment. The screener and orthop-
tist were blinded to each other’s assessments to prevent 
bias of assessment. The within- assessment order of testing 
varied for the orthoptic assessment. However, the order 
of testing within the VISA screen followed a set order of 
(1) case history, (2) visual acuity, (3) eye alignment and 
movement, (4) visual field and (5) visual inattention 
assessments.
Statistical methodology and sample size
Results were taken in numerical format from the referral 
forms completed by both the screener and orthoptist. 
The orthoptic vision assessment was taken as the refer-
ence standard.
The primary outcome measure was a binary measure 
of the presence or absence of visual impairment (defined 
as one or more of the following; reduced distance vision 
<0.2, reduced near vision <0.3 (equivalent to N6), devi-
ated eye position, eye movement abnormality (incomplete 
eye rotations in any position of gaze), visual field loss (eg, 
presence of hemianopia, quadrantanopia, constriction), 
visual inattention with displaced line bisection, <42 score 
on cancellation task and/or incomplete/displaced clock 
drawing). The primary outcome measure was evaluated 
by kappa values assessing chance- eliminated agreement 
between the results of the VISA screening and orthoptic 
vision assessment.
Secondary outcome measures were the calculation of 
sensitivity, specificity and predictive values. Level of sensi-
tivity was estimated as the proportion of patients with 
visual impairment as diagnosed by the gold- standard 
clinical examination, which are correctly identified by 
the screener, and the corresponding 95% CI was calcu-
lated. Level of specificity was estimated as the proportion 
of patients without visual impairment that are correctly 
identified by the screener, and the corresponding 95% 
CI. Further, we calculated the positive and negative 
predictive values for the VISA screen. Kappa (K) values 
assessed chance- eliminated agreement between the indi-
vidual components of VISA tool and orthoptic vision 
assessment. The interpretation used was 0.0–0.2 poor, 
0.21–0.4 fair, 0.41–0.6 moderate, 0.61–0.8 substantial and 
0.81–1.0 almost perfect.18 Analysis was conducted using 
StatsDirect software (StatsDirect).
For sample size, we applied the principles for diagnostic 
accuracy studies, and aimed to recruit a sample of 100 for 
validation of VISA print and a further sample of 100 for 
VISA app.19
Process evaluation
Process evaluation for acceptability of VISA during the 
clinical study was collected via clinician feedback sheets 
and one- to- one reports from patients. Feedback sheets 
could be returned at any time during the study to report 
any issues with testing alongside obtaining clinician views 
based on their use of VISA. Feedback sheets asked the 
following:
1. Are the instructions for the various tests clear?
2. Which instructions should be amended?
3. What additional instruction information/rewording 
do you suggest?
4. Which instructions require less information?
5. Are any tests not useful or difficulty to do? (Specify)
6. Should any other tests be added in?
7. How long does it take you to do the screen?
8. Other comments?
Comments collected from feedback sheets and reports 
were collated descriptively.
Patient and public involvement
Patients were involved in the design and monitoring of 
this study. Patients from the VISable stroke and vision 
panel were consulted when devising the study plan and 
conduct. Reports during the conduct of this study were 
circulated to the VISable panel for patient monitoring 
purposes.
reSultS
Completion rate
Two hundred and twenty- one stroke patients received 
both a VISA screening assessment and a reference vision 
assessment (during the period of September 2016 to 
February 2019).
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Table 1 Calculations of sensitivity, specificity and 
predictive values for VISA print
Positive, that is, pathologic n=86
  True positive, that is, 
visual impairment present 
and referred
84
  False negative, that is, 
visual impairment present 
but not referred
2
Negative that is, normal n=15
  False positive, that is, 
visual impairment not 
present but referred
6
  True negative, that is, 
visual impairment not 
present and not referred
9
Output
  Sensitivity (true positive/
true positive+false 
negative)
97.67%
(95% CI 91.85% to 99.72%)
  Specificity (true negative/
false positive+true 
negative)
60.00%
(95% CI 32.29% to 83.66%)
  Positive predictive 
value (true positive/false 
positive+true positive)
93.33%
(95% CI 88.27% to 96.30%)
  Negative predictive 
value (true negative/false 
negative+true negative)
81.82%
(95% CI 51.83% to 94.95%)
VISA, Vision Impairment Screening Assessment.
All elements of the VISA screen were attempted by 
201 patients. VISA print was used with 121 patients from 
which complete data was available for 101 for analysis. 
The mean age of patients on stroke admission was 70.6 
(SD 13.5), 46 were females and 54 males. The reported 
mean time of test duration was 23.5 min (SD 10.0).
VISA app was completed with 100 patients with a mean 
age of 63.4 (SD 13.4), of which 72 were males and 28 were 
females.
VISA print was fully completed by 91 patients, with 
the remaining 10 missing one or more elements (near 
vision n=5, distance vision n=5, ocular motility n=1, 
visual fields n=1, visual inattention n=9). The orthoptic 
vision assessment was fully completed by 90 patients, with 
the remaining 11 missing one or more elements (near 
vision n=8, visual inattention n=9). Reasons for inability 
to complete one or more of the elements were typically 
recorded as either cognitive impairment or fatigue. VISA 
app and orthoptic vision assessment were fully completed 
by all 100 patients. Missing data did not automatically 
result in failure for that section, thereby requiring 
referral. The reason for failure was taken into account; 
for example, if a section was not completed due to fatigue 
this would not pragmatically have resulted in a referral 
but instead, a retest.
referral agreement for VISA print
The agreement of whether to make a referral to 
specialist eye services based on the results of the VISA 
print versus those from orthoptic vision assessment had 
a kappa value of 0.648 (substantial agreement) (95% CI 
0.424 to 0.872).
Sensitivity of 97.67% and specificity of 60.00% were 
found. The positive and negative predictive values were 
93.33% and 81.82%, respectively. These calculations are 
outlined in table 1. Agreement was found for 93 partici-
pants (9 had no visual impairment, 84 required referral 
because of failed screening) as outlined in figure 1.
VISA print produced two false negative and six false 
positive results. Of the false negative results, both had 
ocular motility problems, of which one also had reduced 
near vision. The two ocular motility problems missed 
were asymptomatic minimal rotary nystagmus and limited 
elevation. The latter also had reduced near vision at 0.450 
LogMAR. For false positive results, three with reduced 
near vison, two with ocular motility problems and one 
with both reduced near vision and visual inattention, were 
detected by screening and found not to be present by 
the orthoptic vision assessment. The referrals relating to 
reduced near vision all detected N8 level of vision in one 
or both eyes. The referral relating to visual inattention 
was detected on the clock drawing element; it was noted 
by the examiner that the inaccurate completion was likely 
due to cognitive impairment. The ocular motility prob-
lems detected were reported as limitation of vertical gaze 
and nystagmus.
test component agreement for VISA print
The agreements for the individual components between 
VISA print and orthoptic vision assessments are outlined 
in table 2. The highest levels of agreement were produced 
for distance visual acuity (0.565) and visual fields (0.504), 
both with moderate agreement. The lowest level of agree-
ment was produced for near visual acuity (0.236) and 
ocular motility (0.367), both with fair agreement. Low 
agreement for ocular motility related to high false posi-
tives and false negatives. Ten cases (one with multiple 
conditions) were not detected (false negative). These 
comprised four defects of vertical movement (including 
one upgaze palsy, two restrictions of elevation and one 
V- pattern), three cases of nystagmus (including one 
minimal rotary nystagmus, one gaze- evoked and one end- 
point nystagmus) and four cases of reduced convergence. 
The low agreement with near visual acuity related to high 
false negatives where 23 cases were not detected—these 
composed of 10 with 0.4 LogMAR or better, nine between 
0.4 and 0.5 LogMAR and three 0.6 LogMAR or worse.
referral agreement for VISA app
The agreement of whether to make a referral to specialist 
eye services based on the results of VISA app versus those 
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Figure 1 Flow diagram of participant outcome for VISA screening and orthoptic full assessment. VISA, Vision Impairment 
Screening Assessment.
Table 2 Summary of agreement between VISA print and orthoptic vision assessment for referral to specialist eye services and 
individual components
Element of testing Agreement False negative False positive Kappa value (95% CI)
Referral 93 2 6 0.648 (0.424 to 0.872)
Near visual acuity 65 23 12 0.236 (0.045 to 0.427)
Distance visual acuity 79 9 13 0.565 (0.405 to 0.725)
Ocular alignment 89 5 7 0.388 (0.110 to 0.667)
Ocular motility 72 10 19 0.367 (0.181 to 0.553)
Visual fields 76 7 18 0.504 (0.339 to 0.668)
Visual inattention 74 4 21 0.500 (0.340 to 0.659)
VISA, Vision Impairment Screening Assessment.
from orthoptic vision assessment had a Kappa value of 
0.690 (substantial agreement) (95% CI 0.528 to 0.851).
Sensitivity of 88.31% and specificity of 86.96% were 
calculated. The positive and negative predictive values 
were 95.77% and 68.97%, respectively. These calculations 
are outlined in table 3.
Agreement was found for 88 participants (20 had no 
visual impairment, 68 required referral because of failed 
screening) as outlined in figure 1. VISA app produced 
nine false negative and three false positive results. Of the 
false negative results, four had slightly reduced near vision 
between 0.3 and 0.4 LogMAR, two had reduced distance 
vision of 0.3 LogMAR, two had mild visual inattention 
(one detected on clock cancellation and was the exam-
iners judgement) and one had reduced near vision of 0.4 
LogMAR and a visual field defect (partial right superior 
quadrantanopia detect on confrontation only, but not 
detected by formal perimetry using binocular Esterman). 
False positive results (one with reduced distance vision, 
one with a visual field defect and one with both a visual 
field defect and visual inattention) were detected by 
screening and found not to be present by the ortho-
ptic vision assessment. The referral relating to reduced 
distance vision was 0.4 LogMAR. The referral relating 
to a visual field defect of general constriction and visual 
inattention was detected on the longest line in the line 
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Table 3 Calculations of sensitivity, specificity and 
predictive values for VISA app
Positive, that is, pathologic n=77
  True positive, that 
is, visual impairment 
present and referred
68
  False negative, that 
is, visual impairment 
present but not referred
9
Negative that is, normal n=23
  False positive, that is, 
visual impairment not 
present but referred
3
  True negative, that is, 
visual impairment not 
present and not referred
20
Output
  Sensitivity (true positive/
true positive+false 
negative)
88.31%
(95% CI 78.97% to 94.51%)
  Specificity (true 
negative/false 
positive+true negative)
86.96%
(95% CI 66.41% to 97.22%)
  Positive predictive 
value (true positive/false 
positive+true positive)
95.77%
(95% CI 88.72% to 98.49%)
  Negative predictive 
value (true negative/false 
negative+true negative)
68.97%
(95% CI 54.10% to 80.73%)
VISA, Vision Impairment Screening Assessment.
Table 4 Summary of agreement between VISA app and orthoptic vision assessment for referral to specialist eye services and 
individual components
Element of testing Agreement False negative False positive Kappa value (95% CI)
Referral 88 9 3 0.690 (0.528 to 0.851)
Near visual acuity 77 19 3 0.416 (0.227 to 0.605)
Distance visual acuity 90 6 4 0.783 (0.656 to 0.910)
Visual fields 85 3 12 0.701 (0.564 to 0.838)
Visual inattention 78 6 16 0.323 (0.108 to 0.538)
VISA, Vision Impairment Screening Assessment.
bisection element. The other visual field defect detected 
was general constriction.
test component agreement for VISA app
The agreements for the individual components between 
VISA app and orthoptic vision assessments are outlined in 
table 4. The highest levels of agreement were produced 
for distance visual acuity (0.783) and visual fields (0.701), 
both with substantial agreement. The lowest level of agree-
ment was produced for visual inattention (0.323) with fair 
agreement. The low agreement with visual inattention 
related to 16 false positives, of which 13 were detected 
with one of the three tests; 12 with line bisection, 1 with 
clock drawing.
Perimetry agreement
Twenty- five participants had formal perimetry using the 
binocular Esterman programme rather than confron-
tation. There was perfect agreement (1.0) of whether a 
visual field defect was present between the kinetic visual 
field test on VISA app versus formal perimetry using the 
binocular Esterman programme. Twenty- one had a visual 
field defect and four were found to have a normal visual 
field.
Process evaluation
Information from feedback sheets and detailed notes 
from interviews were compiled and grouped for type of 
feedback. Minimal feedback was obtained during the 
validation study. Feedback related to the duration of 
screening, presentation of tests on the app and referral 
guides. One stroke unit noted that VISA could take too 
long in the hyperacute stage with unwell patients. Feed-
back on app presentation included a change to the clock 
drawing circle (to remove lines that might indicate time 
markers), change to the fixation target for the visual 
field test, addition of a nystagmus check on eye move-
ment testing (in addition to its presence in the case 
history checklist) and ability to delete erroneous marks 
on the line bisection test. For referral guidance, feed-
back requested the addition of a refer/retest icon on the 
patient results page. Further feedback reported greater 
ease of screening with the app for those having to use 
their non- dominant hand because of upper limb motor 
impairment. Stroke survivors found it easier to respond 
using the touch screen than traditional pen and paper 
tasks when using their non- dominant hand.
dISCuSSIon
In this study, we present the VISA screening tool, performed 
by non- eye trained specialists, with validation results for the 
printed version and for the software app. Overall, referral 
had sensitivity and specificity of >88% and >60%, respec-
tively, positive and negative predictive values of >93% and 
>68%, respectively, with substantial agreement between 
VISA screening and comprehensive orthoptic assessment of 
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about kappa 0.7. Agreement was lowest for eye movement 
screening, near visual acuity and visual inattention whereas 
all other individual sections showed higher levels of agree-
ment. Process evaluation aided further refinement of VISA 
and, in particular, changes to presentation features on the 
app version.
When designing and using screening tools there is a 
balance between sensitivity and specificity for reliable 
detection of deficits. Low agreement in the VISA sections 
related to high false positive referrals where VISA screen 
indicated a fail for ocular motility or visual inattention. 
The orthoptic vision assessment confirmed ocular motility 
changes which were classed as ‘normal’ physiological eye 
movement patterns such age- related reduced elevation, 
and which alone would not have required referral. False 
positive referrals for visual inattention occurred where the 
patient failed to complete the section because of fatigue or 
cognitive impairment. Reduced visual acuity was always at a 
borderline level just above the fail threshold.
False negative referrals are important to consider; failed 
detection of significant deficits is to be avoided. Our results 
showed low numbers of false negatives which included 
failed detection of ocular motility defects, reduced visual 
acuity, visual inattention and visual field defect. The ocular 
motility defects were related to asymptomatic limited eleva-
tion and minimal nystagmus which would not have consti-
tuted referrals by orthoptic vision assessment. Reduced 
visual acuity, similar to the false positive results, was always 
close to the pass/fail threshold. Arguably, this is an ideal call 
for retest rather than refer. One case of mild visual inatten-
tion was not passed by VISA app where the diagnosis had 
been made by clinical observation. One visual field defect 
related to a peripheral field loss; a defect that could not be 
detected by the central testing area of VISA app.
Specificity was higher when using VISA app compared 
with VISA print. Mean age for the VISA app group was 
lower than the VISA print group with more male than 
female participants in the VISA app group. It is unlikely 
that age/sex differences affected agreement between the 
VISA print/app formats versus orthoptic assessment as all 
participants, by default of meeting the inclusion criteria, 
were able to undergo both assessments. Differences are 
more likely due to the staff mix using VISA. VISA print 
was used solely by members of the stroke team and often 
without any formal vision training. VISA app was used by a 
mix of stroke team members but also orthoptists. Accuracy 
was likely enhanced by involvement of the latter. Referral 
agreements overall for decision on making a referral were 
0.648 (VISA print) and 0.690 (VISA app), both indicating 
substantial agreement. It should be noted that kappa is 
dependent on the base rate of the outcome being assessed, 
with calculated values being lower when the prevalence of 
the outcome is either very high or very low. Bruckner and 
Yoder suggest estimating overall accuracy using a combi-
nation of kappa and base rate of outcome.20 This method 
does not change the conclusions drawn here, as these 
outcomes with substantial agreement have estimated accu-
racy of at least 90% when base rate is taken into account, 
and those with moderate agreement at least 85% estimated 
accuracy.
VISA print and app provide a vision screen across the 
main categories of potential visual impairment following 
stroke. Besides a case history section, screening includes 
visual acuity, eye position and movements, visual fields and 
visual inattention. There are potential advantages for using 
either the manual tool or the app. Some clinicians and 
stroke survivors may prefer and respond better to use of 
traditional testing options inclusive of pen and paper tasks. 
The recording charts are completed during the testing 
period and can be entered in hospital case notes immedi-
ately. The app produces a PDF file of results which has to 
be printed before entry in hospital case notes. Conversely, 
the PDF file is an advantage for electronic hospital records. 
Further, the app provides a constant background illumina-
tion for screening assessments whereas the manual is used 
under variable lighting conditions dependent on wher-
ever the screening is undertaken. The app uses a kinetic 
central visual field assessment that is run as a standardised 
test which reduces examiner bias—a bias that persists for 
confrontation visual field assessment.
When developing and validating a screening tool it 
is important that it is compared with a gold standard. In 
our UK services, the gold standard is an orthoptic assess-
ment undertaken on the acute stroke unit. The develop-
ment and pilot of VISA followed a robust process.14 In this 
follow- on validation study we considered the results of VISA 
versus the gold- standard orthoptic assessment in evalu-
ating construct and content validity. We further considered 
ecological validity through use of the tool by clinical (not 
research) stroke teams in the real- world environment of 
busy acute stroke units in the UK National Health Service 
(NHS). Additionally, we sought specific feedback through 
process evaluation collecting feedback forms from stroke 
team clinicians and patient reports.
A systematic review of screening options for poststroke 
visual impairment reported vision screening checklists and 
stroke screening tools (eg, National Institute for Health 
Stroke Scale (NIHSS), Face Arm Speech Test - Ataxia, 
Visual field defect, Vertigo, Vomiting (FAST- AVVV), Ataxia, 
Blindness, Consciousness, Dysphagia, Eye 1 (diplopia), 
Eye 2 (pupils) (ABCD- E2)) which include elements of 
vision assessment, however, not all potential visual impair-
ments are screened.21 Past vision screening publications 
have reported the results of vision ‘checklists’—lists of 
information gathered from questioning the patient, obser-
vations or from data documented in the case notes. The 
Vision In Stroke (VIS) study reported checklist screening 
in 915 stroke survivors with sensitivity of 0.42, specificity of 
0.52 and agreement against a reference standard of 0.428 
(95% CI −0.048 to 0.019: kappa).2 12 An Australian study 
reported the use of a checklist for detection of eye condi-
tions and vision defects in 100 stroke survivors with 69% 
accuracy and intraclass correlation of 0.84 (95% CI 0.77 to 
0.89).22 More recently, a vision screening app (available on 
android platforms) was developed for use with stroke survi-
vors (StrokeVision app) with sections assessing visual acuity, 
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visual fields and visual inattention.23 This was validated with 
a cohort of 45 stroke survivors with sensitivities across the 
various sections of 50%–79% and specificities of 87%–98%. 
The specificities reported are higher than those from our 
VISA study but likely reflect the use of the StrokeVision 
app by fully trained research assistants vs the VISA comple-
tion by members of the stroke MDT who only followed the 
in- built screening instructions.
Overall, vision tools/apps provide a more extensive 
screening of vision with greater accuracy than vision check-
lists. However, there are issues with how best to identify the 
presence of visual impairment through stroke team vision 
screening and specialist vision assessment.21 24 Even with 
screening measures in place, there are also issues reported 
with provision of care and access to vision services for 
stroke survivors who have been identified as having vision 
problems.13
An ideal stroke vision service follows recommendations 
from the National Clinical Guidelines for Stroke which 
specify orthoptists as core members of the acute stroke 
team and screen all stroke survivors prior to discharge.16 
Despite consistent findings that inclusion of vision services 
within the MDT is highly beneficial, such visual assessment 
is not common and services are inconsistent throughout 
the UK. Stepped models of care must be considered to 
meet the needs of stroke survivors against the context of 
local service capacity. Access to orthoptic services on acute 
stroke units enables faster provision of vision screening. 
The earlier assessment time point reported for the IVIS 
study is important as it shows the feasibility and acceptability 
of early visual assessment within 3 days of stroke onset for 
at least half of stroke survivors and within 1 week of stroke 
onset for the majority.4 Early detection of visual impairment 
is important. Although some cases of visual impairment will 
recover quickly, the majority do not. Moreover, there are 
few predictive factors for who will recover.4 This prompt 
early detection, in turn, allows early detection of visual 
impairment and sharing of the functional significance of 
this with the patients, carers and stroke teams. Further-
more, early assessment leads to early intervention which 
has potential impact on general rehabilitation where visual 
function can be improved.2 3 10 In the absence of orthoptic 
services, further stepped down models of care include the 
use of screening tools or screening checklists.
Such screening methods cannot replace the accuracy of a 
reference, specialist vision assessment. However, they serve 
an important purpose of obtaining a standardised screen 
in the absence of on- site specialist vision services and are 
better than no or non- standardised assessments by non- eye 
trained clinicians. In such instances, we advise the use of a 
screening tool. The advantages of VISA print and app are 
their validation in a real- world pragmatic study conducted 
in acute stroke units and used by non- eye trained clini-
cians. Clinicians used the in- built standalone instructions—
designed to avoid the need of regular specialist vision 
training which can be difficult to access or provide. Further, 
the app is MHRA approved for clinical assessment; an 
important requirement for NHS adoption. The availability 
of VISA as a manual and as an app facilitates use alongside 
paper- based records or integration with electronic patient 
record systems.
Vision checklists have been shown to have a low sensi-
tivity and specificity, and an over- reliance on the report of 
visual symptoms.2 12 The VISA print and app offer an inter-
mediate measure between vision checklists and orthoptic 
specialist vision services with greater accuracy than vision 
checklists but lacking the accuracy of orthoptic assessments 
and the immediate access to management of visual prob-
lems provided by orthoptic stroke unit services. The VISA 
print/app does not preclude the use of vision checklists, 
however, for some stroke survivors who are very unwell 
acutely and/or lack sufficient cognition and communica-
tion. Simpler vision checklists are quick and easy to use in 
such circumstances and remain more accurate than no 
vision screen at all.
There are some limitations to consider for this study. 
The VISA screening tool was used on acute stroke units. 
There was no validation of the tool in community settings. 
However, there is little reason to think it would be of less 
use or accuracy when used in other stroke settings. Test–
retest and inter- rater variability of the VISA screening tool 
were not evaluated during this study as this would have 
caused too high a burden of assessment on participants. 
Information on education level, stroke type, stroke severity 
and ocular history were not obtained for this study. These 
sources of information were not considered essential to this 
study as the primary aim was to determine if VISA could 
detect visual impairment regardless of patient/stroke 
demographics and regardless of whether visual impair-
ment was new or pre- existent. These aspects would provide 
potentially useful discussion in a future implementation 
study of VISA. A further limitation is that we included a 
convenience sample of stroke survivors in this study. The 
study was designed as a pragmatic clinical study to fit in 
with daily clinical practice and with minimal disruption to 
service and care on the acute stroke unit. As a result the 
stroke team were potentially more likely to screen stroke 
survivors at risk for visual impairment. This may explain the 
higher prevalence rate of visual impairment for this study 
(85% VISA print and 77% VISA app) than that reported in 
a recent epidemiology study (73%).4
ConCluSIonS
Validation of the VISA screening tool in either print or app 
format shows improved detection accuracy for detection of 
stroke- related visual impairment by clinicians involved in 
stroke care who are not specialists in vision problems and 
lack formal eye training. Where early visual impairment 
detection occurs, this facilitates prompt referral with fewer 
false positives and negatives. Clinicians reported accept-
ability of the VISA screening tool for is use in screening for 
presence of vision problems in stroke survivors. Referral 
sensitivity of >88% and specificity of >60% were found 
for the VISA screening with substantial inter- rater agree-
ment for referral between VISA screening and specialist 
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vision assessments. The VISA screening tool provides a 
standardised and validated method to screen for visual 
problems following stroke and may further be of poten-
tial use for visual screening in other care settings such as 
neurorehabilitation.
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